KR20240142567A - 중수소화 또는 부분적 중수소화 n,n-다이메틸트립타민 화합물을 포함하는 치료 조성물 - Google Patents

중수소화 또는 부분적 중수소화 n,n-다이메틸트립타민 화합물을 포함하는 치료 조성물 Download PDF

Info

Publication number
KR20240142567A
KR20240142567A KR1020247030292A KR20247030292A KR20240142567A KR 20240142567 A KR20240142567 A KR 20240142567A KR 1020247030292 A KR1020247030292 A KR 1020247030292A KR 20247030292 A KR20247030292 A KR 20247030292A KR 20240142567 A KR20240142567 A KR 20240142567A
Authority
KR
South Korea
Prior art keywords
dimethyltryptamine
composition
compounds
dideutero
deuterated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020247030292A
Other languages
English (en)
Korean (ko)
Inventor
피터 랜즈
젤라 조엘
티파니 벤웨이
Original Assignee
사이빈 유케이 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사이빈 유케이 리미티드 filed Critical 사이빈 유케이 리미티드
Publication of KR20240142567A publication Critical patent/KR20240142567A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020247030292A 2019-06-03 2020-06-02 중수소화 또는 부분적 중수소화 n,n-다이메틸트립타민 화합물을 포함하는 치료 조성물 Ceased KR20240142567A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB1907871.6 2019-06-03
GBGB1907871.6A GB201907871D0 (en) 2019-06-03 2019-06-03 Therapeutic compositions
PCT/EP2020/065244 WO2020245133A1 (en) 2019-06-03 2020-06-02 Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
KR1020217043410A KR20220034061A (ko) 2019-06-03 2020-06-02 중수소화 또는 부분적 중수소화 n,n-다이메틸트립타민 화합물을 포함하는 치료 조성물

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217043410A Division KR20220034061A (ko) 2019-06-03 2020-06-02 중수소화 또는 부분적 중수소화 n,n-다이메틸트립타민 화합물을 포함하는 치료 조성물

Publications (1)

Publication Number Publication Date
KR20240142567A true KR20240142567A (ko) 2024-09-30

Family

ID=67385960

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247030292A Ceased KR20240142567A (ko) 2019-06-03 2020-06-02 중수소화 또는 부분적 중수소화 n,n-다이메틸트립타민 화합물을 포함하는 치료 조성물
KR1020217043410A Ceased KR20220034061A (ko) 2019-06-03 2020-06-02 중수소화 또는 부분적 중수소화 n,n-다이메틸트립타민 화합물을 포함하는 치료 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217043410A Ceased KR20220034061A (ko) 2019-06-03 2020-06-02 중수소화 또는 부분적 중수소화 n,n-다이메틸트립타민 화합물을 포함하는 치료 조성물

Country Status (20)

Country Link
US (3) US12076311B2 (cg-RX-API-DMAC10.html)
EP (2) EP4062910B1 (cg-RX-API-DMAC10.html)
JP (1) JP7523474B2 (cg-RX-API-DMAC10.html)
KR (2) KR20240142567A (cg-RX-API-DMAC10.html)
CN (1) CN114096246B (cg-RX-API-DMAC10.html)
AU (1) AU2020286709B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021024333A2 (cg-RX-API-DMAC10.html)
CA (2) CA3142290C (cg-RX-API-DMAC10.html)
DK (1) DK3826632T3 (cg-RX-API-DMAC10.html)
EA (1) EA202193338A1 (cg-RX-API-DMAC10.html)
ES (1) ES2922101T3 (cg-RX-API-DMAC10.html)
GB (4) GB201907871D0 (cg-RX-API-DMAC10.html)
HR (1) HRP20220837T8 (cg-RX-API-DMAC10.html)
HU (1) HUE059439T2 (cg-RX-API-DMAC10.html)
IL (1) IL288617B2 (cg-RX-API-DMAC10.html)
MX (1) MX2021014728A (cg-RX-API-DMAC10.html)
PL (1) PL3826632T3 (cg-RX-API-DMAC10.html)
PT (1) PT3826632T (cg-RX-API-DMAC10.html)
TW (1) TWI860478B (cg-RX-API-DMAC10.html)
WO (1) WO2020245133A1 (cg-RX-API-DMAC10.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
HRP20220797T1 (hr) * 2019-11-07 2022-10-14 Small Pharma Ltd Spojevi
AU2021215709A1 (en) 2020-02-04 2022-09-01 Mindset Pharma Inc. 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders
MX2022009527A (es) 2020-02-04 2022-11-16 Mindset Pharma Inc Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc.
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
IL312785B2 (en) 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
GB2605144A (en) * 2021-03-22 2022-09-28 Small Pharma Ltd Deuterated compounds
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
CN116056763B (zh) * 2020-06-02 2024-03-05 赛本英国有限公司 包含氘代或部分氘代的n,n-二甲基色胺化合物的治疗组合物
WO2021116503A2 (en) * 2020-06-02 2021-06-17 Small Pharma Ltd Deuterated compounds
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
JP2023539113A (ja) 2020-08-18 2023-09-13 サイビン アイアールエル リミテッド フェネチルアミン誘導体、組成物およびその使用方法
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
EP4138818B1 (en) * 2020-08-28 2024-08-21 Cybin UK Ltd Injectable formulation
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
US12521370B2 (en) 2020-12-01 2026-01-13 Cybin Uk Ltd Inhalable formulations
EP4031529B1 (en) 2020-12-01 2023-09-27 Small Pharma Ltd Deuterated or partially deuterated n,n-dimethyltryptamine compounds
WO2022120181A1 (en) * 2020-12-03 2022-06-09 Mydecine Innovations Group Inc. Novel psilocin analog compositions and methods of synthesizing the same
MX2023010317A (es) * 2021-03-02 2023-11-09 Mindset Pharma Inc Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos.
US20230136824A1 (en) 2021-04-26 2023-05-04 ATAI Life Sciences AG N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof
CA3216889A1 (en) * 2021-04-26 2022-11-03 Glenn Short Novel n,n-dimethyltryptamine compositions and methods
CA3217559A1 (en) * 2021-05-05 2022-11-10 Kamaluddin Abdur-Rashid Catalytic tryptamine processes and precursors
EP4792879A2 (en) * 2021-05-17 2026-08-19 Cybin IRL Limited Formulations of psilocybin
KR20240013170A (ko) * 2021-05-25 2024-01-30 아타이 테라퓨틱스, 인크. 신규 n,n-디메틸트립타민 염 및 결정질 염 형태
KR20240017363A (ko) * 2021-06-02 2024-02-07 세인트 조셉스 유니버시티 플루오린화 트립타민 화합물, 이의 유사체 및 이를 사용하는 방법
IL309210A (en) 2021-06-09 2024-02-01 Atai Therapeutics Inc Parent drugs and conjugates of dimethyltryptamine
WO2023018864A1 (en) 2021-08-12 2023-02-16 Psilosterics, Llc Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same
WO2023028091A1 (en) * 2021-08-23 2023-03-02 Alexander Shulgin Research Institute Deuterated empathogens
CA3229910A1 (en) * 2021-08-23 2023-03-02 Alexander Shulgin Research Institute, Inc. Fluorinated empathogens
US11697638B2 (en) 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
AU2022342266B2 (en) * 2021-09-08 2026-03-26 Cybin Irl Limited Combination drug therapies
EP4159192A1 (en) 2021-09-30 2023-04-05 Biomind Labs Inc Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders
EP4159201A1 (en) 2021-09-30 2023-04-05 Biomind Labs Inc Encapsulated microparticles and nanoparticles of dimethyltriptamines
WO2023076135A1 (en) * 2021-10-29 2023-05-04 Psilera Inc. N,n-dimethyltryptamine (dmt) crystalline products and methods of making the same
EP4433049A1 (en) 2021-11-18 2024-09-25 Cybin UK Ltd Injectable and inhalable formulations
US12318477B2 (en) 2021-11-18 2025-06-03 Cybin Uk Ltd Injectable and inhalable formulations
CA3238440A1 (en) 2021-12-30 2023-07-06 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
US20250205198A1 (en) * 2022-03-31 2025-06-26 Cybin Irl Limited Methods for delivery of psychedelic medications by inhalation and systems for performing the methods
EP4522167A1 (en) 2022-05-10 2025-03-19 Mydecine Innovations Group Inc. Novel psilocin prodrug compounds and methods of synthesizing the same
WO2024108195A1 (en) 2022-11-17 2024-05-23 Remedi, Inc. Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use
US20240325351A1 (en) 2023-03-31 2024-10-03 Cybin UK Ltd. Method of administration
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same
TW202617141A (zh) 2024-07-10 2026-05-01 英商賽本英國有限公司 包含氘化n,n-二甲基色胺之醫藥組合物

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4336378A (en) 1980-04-10 1982-06-22 Sandoz, Inc. Isoxazolyl indolamines
AU1928892A (en) 1991-06-21 1993-01-25 Smithkline Beecham Plc Tryptamine analogues, their synthesis and their use as 5-ht1-like or 5-ht2 receptor agonists
US6376531B1 (en) 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
WO2001097779A2 (en) 2000-06-16 2001-12-27 Rtp Pharma Inc. Improved injectable dispersions of propofol
ITRM20010356A1 (it) 2001-06-21 2002-12-23 Sigma Tau Ind Farmaceuti "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
WO2004085392A1 (en) 2003-03-25 2004-10-07 Faust Pharmaceuticals Melatonin derivatives and their use for treating neurological dysfunctions
WO2008049116A2 (en) 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
WO2008071455A1 (en) 2006-12-15 2008-06-19 Bayer Schering Pharma Aktiengesellschaft Bicyclic acyltryptophanols
CZ302424B6 (cs) 2007-06-13 2011-05-11 Zentiva, A. S. Zpusob prípravy almotriptanu o vysoké cistote
US20090076121A1 (en) 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched sumatriptan
EP2209380A4 (en) 2007-10-09 2011-09-14 Mark T Hamann METHOD OF USE OF COMPOSITIONS WITH ANTIDEPRESSIVE EFFICACY, MOOD EFFICACY AND OTHER NEUROLOGICAL EFFECTIVENESS AND COMPOSITIONS THEREOF
US20100069399A1 (en) * 2008-09-15 2010-03-18 Auspex Pharmaceutical, Inc. Arylpiperazine modulators of d2 receptors, 5-ht1a receptors, and/or 5-ht2a receptors
JP6367545B2 (ja) 2013-12-17 2018-08-01 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
EP3519816A4 (en) 2016-09-29 2020-05-06 The Regents of the University of California CONNECTIONS FOR INCREASING NEURONAL PLASTICITY
JP7273731B2 (ja) 2017-02-09 2023-05-15 カームテック、エルエルシー シロシビン誘導体を含む組成物及び方法
US20200147038A1 (en) 2017-04-20 2020-05-14 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
CN109251151A (zh) * 2017-07-12 2019-01-22 北京广为医药科技有限公司 N-(2-(取代-萘-1-基)乙基)取代酰胺类化合物、其制备及其用途
US11723894B2 (en) * 2017-10-26 2023-08-15 Terran Biosciences, Inc. Combination product for the treatment of neurological and/or psychiatric disorders
US11117870B2 (en) 2017-11-01 2021-09-14 Drexel University Compounds, compositions, and methods for treating diseases
DK3927338T3 (da) 2019-02-22 2025-01-06 Gh Res Ireland Limited Sammensætninger omfattende 5-methoxy-n,n-dimethyltryptamin (5-meo-dmt) til anvendelse i behandling af mentale lidelser
HUE066828T2 (hu) 2019-02-22 2024-09-28 Gh Res Ireland Limited 5-Metoxi-N,N-Dimetiltriptamin (5-Meo-Dmt) súlyos depressziós rendellenesség kezelésére
WO2020176597A1 (en) 2019-02-27 2020-09-03 The Regents Of The University Of California N-substituted indoles and other heterocycles for treating brain disorders
KR102946120B1 (ko) 2019-02-27 2026-03-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
HRP20220797T1 (hr) 2019-11-07 2022-10-14 Small Pharma Ltd Spojevi
MX2022009527A (es) 2020-02-04 2022-11-16 Mindset Pharma Inc Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc.
IL312785B2 (en) 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
WO2021116503A2 (en) 2020-06-02 2021-06-17 Small Pharma Ltd Deuterated compounds
GB202008961D0 (en) 2020-06-12 2020-07-29 Beckley Psytech Ltd Pharmaceutical composition
CA3188263A1 (en) 2020-08-05 2022-02-10 Matthias Emanuel LIECHTI Intravenous dmt administration method for dmt-assisted psychotherapy
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
EP4138818B1 (en) 2020-08-28 2024-08-21 Cybin UK Ltd Injectable formulation
US20220062237A1 (en) 2020-08-28 2022-03-03 Small Pharma Ltd Injectable formulation
EP4221682A2 (en) 2020-10-02 2023-08-09 Cybin IRL Limited Methods for delivery of psychedelic medications by inhalation and systems for performing the methods
US11000534B1 (en) 2020-10-08 2021-05-11 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psilocybin and uses thereof
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
EP4031529B1 (en) 2020-12-01 2023-09-27 Small Pharma Ltd Deuterated or partially deuterated n,n-dimethyltryptamine compounds
US12521370B2 (en) 2020-12-01 2026-01-13 Cybin Uk Ltd Inhalable formulations
US11697638B2 (en) 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
US12318477B2 (en) 2021-11-18 2025-06-03 Cybin Uk Ltd Injectable and inhalable formulations

Also Published As

Publication number Publication date
GB2592822A (en) 2021-09-08
PL3826632T3 (pl) 2022-08-01
CA3104072A1 (en) 2021-06-28
EA202193338A1 (ru) 2022-03-02
GB2586940B (en) 2023-07-05
US20200390746A1 (en) 2020-12-17
IL288617B2 (en) 2025-02-01
ES2922101T3 (es) 2022-09-08
DK3826632T3 (da) 2022-07-11
HUE059439T2 (hu) 2022-11-28
GB2585978B (en) 2021-07-14
GB2592822B (en) 2023-07-05
EP4062910B1 (en) 2025-12-24
EP3826632A1 (en) 2021-06-02
MX2021014728A (es) 2022-03-11
JP7523474B2 (ja) 2024-07-26
TW202210075A (zh) 2022-03-16
CA3142290C (en) 2025-03-04
IL288617A (en) 2022-02-01
US20220168275A1 (en) 2022-06-02
KR20220034061A (ko) 2022-03-17
CN114096246B (zh) 2024-11-22
EP4062910A1 (en) 2022-09-28
US12076311B2 (en) 2024-09-03
AU2020286709B2 (en) 2024-05-09
HRP20220837T8 (hr) 2023-02-03
WO2020245133A1 (en) 2020-12-10
PT3826632T (pt) 2022-07-11
GB201907871D0 (en) 2019-07-17
GB202008303D0 (en) 2020-07-15
CA3142290A1 (en) 2020-12-10
GB2586940A (en) 2021-03-10
GB202107702D0 (en) 2021-07-14
US20240374565A1 (en) 2024-11-14
CN114096246A (zh) 2022-02-25
NZ783166A (en) 2025-06-27
BR112021024333A2 (pt) 2022-02-08
JP2022535093A (ja) 2022-08-04
US11771681B2 (en) 2023-10-03
CA3104072C (en) 2022-07-19
IL288617B1 (en) 2024-10-01
EP3826632B1 (en) 2022-05-18
AU2020286709A1 (en) 2022-01-06
TWI860478B (zh) 2024-11-01
HRP20220837T1 (hr) 2022-10-14
GB202100807D0 (en) 2021-03-10
GB2585978A (en) 2021-01-27

Similar Documents

Publication Publication Date Title
EP4062910B1 (en) Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
JP7579888B2 (ja) 治療用固形製剤
US12042564B2 (en) Therapeutic solid dosage forms
US20230086574A1 (en) 5-methoxy-n,n-dimethyltryptamine crystalline forms
US20220169606A1 (en) Compositions and compounds for bioanalysis
HK40060891A (en) Therapeutic compositions
HK40081622A (en) Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
EA046951B1 (ru) Терапевтические композиции, включающие дейтерированные или частично дейтерированные соединения n,n-диметилтриптамина
HK40045846A (en) Therapeutic compositions
US20240342101A1 (en) Therapeutic solid dosage forms
HK40064531A (en) Therapeutic solid dosage forms
HK40120570A (en) Therapeutic solid dosage forms

Legal Events

Date Code Title Description
A107 Divisional application of patent
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000